SCOTUS Unveils Final Docket Additions as Term Winds Down: Six New Cases Spanning Drug Patents, Criminal Procedure, and Corporate Arbitration
Among the newly added disputes is Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a patent clash originating from the Federal Circuit that could reshape how generic drug manufacturers navigate FDA approval pathways when branded rivals hold overlapping intellectual property claims. The case arrives as the pharmaceutical industry grapples with mounting pressure to lower medication costs while protecting innovation incentives.
The justices also agreed to hear Chatrie v. United States, a Fourth Circuit case raising thorny questions about geofence warrantsβthe increasingly common police practice of demanding location data from tech companies for every device that pinged a cell tower near a crime scene. Privacy advocates have long argued these sweeping digital searches violate Fourth Amendment protections, while law enforcement maintains they’re essential tools for solving crimes in an interconnected world. With the Court already having tackled similar surveillance questions in recent terms, Chatrie offers the justices another opportunity to draw boundaries around constitutional privacy in the smartphone era.

Corporate America will be watching closely when the Court hears Anderson v. Intel Corporation Investment Policy Committee, a Ninth Circuit dispute involving pension fund management and the scope of fiduciary duties under ERISA. The case could clarify when employers face liability for investment decisions that affect retirement savings, an issue affecting millions of workers nationwide.
The criminal docket also received fresh entries. Klein v. Martin presents another Fourth Circuit matter, this time concerning procedural rules and the limits of federal habeas corpus review. While less headline-grabbing than some of the Court’s high-profile constitutional cases, these procedural disputes often determine whether incarcerated individuals receive meaningful access to federal courts.
Rounding out the new grants are Monsanto Company v. Durnell, a Missouri case involving agricultural giant Bayer’s liability disputes, and Salazar v. Paramount Global, a Sixth Circuit matter touching on media and employment law. Together, these six additions bring the term’s total merits docket to approximately 60 cases, with oral arguments scheduled through April.
The timing matters. With the Court having already heard arguments in blockbuster cases involving presidential tariff authority, the independence of federal agencies, and transgender rights earlier this term, these late additions suggest the justices are cleaning up circuit splits and resolving persistent legal ambiguities before the October 2026 term begins.
Notably absent from the recent grant list were several high-profile petitions involving election law and social media regulationβissues that have dominated public discourse but which the Court appears content to let percolate in lower courts for now. The justices also declined to intervene in a challenge to Pennsylvania’s mail-in ballot counting procedures, though they did recently rule that a Republican congressman had standing to bring a similar challenge in Illinois.
As briefing proceeds in these newly granted cases, Court watchers expect the justices to release opinions in the coming months on the term’s most contentious disputes, including whether President Trump possessed legal authority to impose sweeping tariffs under a 1977 emergency powers statuteβa case argued in November that could define the boundaries of executive economic authority for decades.
Disclaimer: